Symbols / RLMD Stock $7.21 -0.55% Relmada Therapeutics, Inc.

Healthcare • Biotechnology • United States • NCM
RLMD (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Sergio Traversa M.B.A., Pharm.D.
Exch · Country NCM · United States
Market Cap 756.26M
Enterprise Value -34.18M
Income -15.01M
Sales —
FCF (ttm) -7.74M
Book/sh 1.18
Cash/sh 10.22
Employees 17
Insider 10d —
IPO Jun 20, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -17.59
PEG —
P/S —
P/B 6.11
P/C —
EV/EBITDA 2.47
EV/Sales —
Quick Ratio 79.92
Current Ratio 80.21
Debt/Eq 0.10
LT Debt/Eq —
EPS (ttm) -1.45
EPS next Y -0.41
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-11
Earnings (prior) 2026-03-19
ROA -14.38%
ROE -25.62%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 104.89M
Shs Float 7.72M
Insider Own 7.52%
Instit Own 51.20%
Short Float 6.28%
Short Ratio 4.61
Short Interest 6.19M
52W High 7.94
vs 52W High -9.19%
52W Low 0.27
vs 52W Low 2,590.30%
Beta —
Impl. Vol. 43.87%
Rel Volume 0.39
Avg Volume 1.74M
Volume 681.27K
Target (mean) $12.80
Tgt Median $12.00
Tgt Low $9.00
Tgt High $19.00
# Analysts 5
Recom Strong_buy
Prev Close $7.25
Price $7.21
Change -0.55%
About

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$12.80
Mean price target
2. Current target
$7.21
Latest analyst target
3. DCF / Fair value
$-1.33
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$7.21
Low
$9.00
High
$19.00
Mean
$12.80

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-24 init Piper Sandler — → Overweight $12
2026-03-20 main Mizuho Outperform → Outperform $19
2026-03-02 init LUCID CAPITAL MARKETS — → Buy $14
2026-01-23 up Leerink Partners Market Perform → Outperform $8
2025-12-22 init Jefferies — → Buy $9
2025-11-19 up Mizuho Neutral → Outperform $10
2024-12-05 down Mizuho Outperform → Neutral $1
2024-12-04 down Leerink Partners Outperform → Market Perform $1
2024-06-05 down Goldman Sachs Neutral → Sell $2
2023-06-15 reit Mizuho Buy → Buy $26
2023-01-23 main SVB Leerink — → Outperform $10
2022-10-14 down Goldman Sachs Buy → Neutral $8
2022-10-14 down Guggenheim Buy → Neutral —
2022-10-13 down Oppenheimer Outperform → Perform —
2022-09-23 main Goldman Sachs — → Buy $81
2022-09-06 main Guggenheim — → Buy $60
2022-05-09 main Oppenheimer — → Outperform $64
2022-03-24 main Goldman Sachs — → Buy $53
2021-12-20 main SVB Leerink — → Outperform $42
2021-11-18 init Mizuho — → Buy $50
News
RSS: Latest RLMD news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-15 TRAVERSA SERGIO Chief Executive Officer — 27,500 $4.12 $113,300
2025-12-15 SHENOUDA MAGED R Chief Financial Officer — 11,665 $4.12 $48,060
2025-11-05 TRAVERSA SERGIO Chief Executive Officer — 272,500 $2.20 $599,500
2025-11-05 SHENOUDA MAGED R Chief Financial Officer — 500,000 $2.20 $1,100,000
2025-11-05 KELLY PAUL EDWARD Chief Operating Officer — 90,000 $2.20 $198,000
2025-11-05 ENCE CHARLES Chief Operating Officer — 136,000 $2.20 $299,200
2025-08-28 TRAVERSA SERGIO Chief Executive Officer — 265,976 $0.62 $178,095
2025-05-20 TRAVERSA SERGIO Chief Executive Officer — 350,000 $0.45 $174,713
2025-05-20 SHENOUDA MAGED R Chief Financial Officer — 200,000 $0.44 $97,208
2025-05-16 KELLY PAUL EDWARD Chief Operating Officer — 200,000 $0.43 $86,060
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
59.10
-29.55%
83.89
-19.10%
103.70
-35.69%
161.25
Research And Development
26.88
-41.79%
46.18
-15.75%
54.81
-51.64%
113.32
Selling General And Administration
32.22
-14.57%
37.72
-22.86%
48.89
+2.02%
47.93
General And Administrative Expense
32.22
-14.57%
37.72
-22.86%
48.89
+2.02%
47.93
Other Gand A
32.22
-14.57%
37.72
-22.86%
48.89
+2.02%
47.93
Total Expenses
59.10
-29.55%
83.89
-19.10%
103.70
-35.69%
161.25
Operating Income
-59.10
+29.55%
-83.89
+19.10%
-103.70
+35.69%
-161.25
Total Operating Income As Reported
-59.10
+29.55%
-83.89
+19.10%
-103.70
+35.69%
-161.25
EBITDA
-59.10
+29.55%
-83.89
+19.10%
-103.70
+35.69%
-161.25
Normalized EBITDA
-59.42
+29.49%
-84.27
+18.55%
-103.46
+33.87%
-156.44
Reconciled Depreciation
—
—
—
0.00
EBIT
-59.10
+29.55%
-83.89
+19.10%
-103.70
+35.69%
-161.25
Total Unusual Items
0.32
-16.41%
0.38
+258.26%
-0.24
+94.98%
-4.81
Total Unusual Items Excluding Goodwill
0.32
-16.41%
0.38
+258.26%
-0.24
+94.98%
-4.81
Net Income
-57.39
+28.25%
-79.98
+19.04%
-98.79
+37.09%
-157.04
Pretax Income
-57.39
+28.25%
-79.98
+19.04%
-98.79
+37.09%
-157.04
Net Non Operating Interest Income Expense
1.40
-60.45%
3.53
-31.48%
5.15
+93.72%
2.66
Net Interest Income
1.40
-60.45%
3.53
-31.48%
5.15
+93.72%
2.66
Interest Income Non Operating
1.40
-60.45%
3.53
-31.48%
5.15
+93.72%
2.66
Interest Income
1.40
-60.45%
3.53
-31.48%
5.15
+93.72%
2.66
Other Income Expense
0.32
-16.41%
0.38
+258.26%
-0.24
-115.60%
1.55
Other Non Operating Income Expenses
—
—
—
6.35
Gain On Sale Of Security
0.32
-16.41%
0.38
+258.26%
-0.24
+94.98%
-4.81
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-57.39
+28.25%
-79.98
+19.04%
-98.79
+37.09%
-157.04
Net Income From Continuing Operation Net Minority Interest
-57.39
+28.25%
-79.98
+19.04%
-98.79
+37.09%
-157.04
Net Income From Continuing And Discontinued Operation
-57.39
+28.25%
-79.98
+19.04%
-98.79
+37.09%
-157.04
Net Income Continuous Operations
-57.39
+28.25%
-79.98
+19.04%
-98.79
+37.09%
-157.04
Normalized Income
-57.70
+28.19%
-80.36
+18.46%
-98.55
+35.27%
-152.24
Net Income Common Stockholders
-57.39
+28.25%
-79.98
+19.04%
-98.79
+37.09%
-157.04
Diluted EPS
-1.45
+45.28%
-2.65
+19.21%
-3.28
+38.11%
-5.30
Basic EPS
-1.45
+45.28%
-2.65
+19.21%
-3.28
+38.11%
-5.30
Basic Average Shares
39.48
+30.88%
30.16
+0.21%
30.10
+1.59%
29.63
Diluted Average Shares
39.48
+30.88%
30.16
+0.21%
30.10
+1.59%
29.63
Diluted NI Availto Com Stockholders
-57.39
+28.25%
-79.98
+19.04%
-98.79
+37.09%
-157.04
Line Item Trend 2023-12-31
Total Assets
97.55
Current Assets
97.51
Cash Cash Equivalents And Short Term Investments
96.32
Cash And Cash Equivalents
4.09
Cash Financial
—
Other Short Term Investments
92.23
Receivables
0.00
Other Receivables
—
Prepaid Assets
1.19
Other Current Assets
—
Total Non Current Assets
0.04
Net PPE
—
Gross PPE
—
Accumulated Depreciation
—
Machinery Furniture Equipment
—
Other Non Current Assets
0.04
Total Liabilities Net Minority Interest
12.19
Current Liabilities
12.19
Payables And Accrued Expenses
9.19
Payables
3.51
Accounts Payable
3.51
Current Accrued Expenses
5.68
Employee Benefits
0.00
Pensionand Other Post Retirement Benefit Plans Current
3.00
Other Current Liabilities
-0.00
Total Non Current Liabilities Net Minority Interest
0.00
Stockholders Equity
85.36
Common Stock Equity
85.36
Capital Stock
0.03
Common Stock
0.03
Preferred Stock
0.00
Share Issued
30.10
Ordinary Shares Number
30.10
Treasury Shares Number
0.00
Additional Paid In Capital
646.23
Retained Earnings
-560.90
Total Equity Gross Minority Interest
85.36
Total Capitalization
85.36
Working Capital
85.31
Invested Capital
85.36
Net Tangible Assets
85.36
Tangible Book Value
85.36
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-45.79
+11.53%
-51.76
-0.19%
-51.66
+50.23%
-103.80
Cash Flow From Continuing Operating Activities
-45.79
+11.53%
-51.76
-0.19%
-51.66
+50.23%
-103.80
Net Income From Continuing Operations
-57.39
+28.25%
-79.98
+19.04%
-98.79
+37.09%
-157.04
Depreciation Amortization Depletion
—
—
—
0.00
Depreciation
—
—
—
0.00
Depreciation And Amortization
—
—
—
0.00
Other Non Cash Items
0.91
—
—
-6.35
Stock Based Compensation
14.96
-50.44%
30.19
-31.09%
43.81
-0.87%
44.19
Operating Gains Losses
0.08
+121.13%
-0.37
-109.22%
4.06
+594.15%
0.59
Gain Loss On Investment Securities
0.08
+121.13%
-0.37
-109.22%
4.06
+594.15%
0.59
Unrealized Gain Loss On Investment Securities
-0.40
-5813.21%
-0.01
+99.82%
-3.82
-190.59%
4.22
Change In Working Capital
-3.95
-149.40%
-1.58
-151.41%
3.08
-70.92%
10.59
Change In Receivables
—
0.00
-100.00%
0.51
+220.27%
-0.43
Change In Prepaid Assets
-0.09
-127.77%
0.32
-88.75%
2.84
-60.85%
7.26
Change In Payables And Accrued Expense
-3.86
-102.84%
-1.90
-594.48%
-0.27
-107.29%
3.76
Change In Accrued Expense
-1.30
+48.61%
-2.53
-270.60%
1.48
-55.61%
3.34
Change In Payable
-2.56
-510.15%
0.62
+135.57%
-1.76
-517.05%
0.42
Change In Account Payable
-2.56
-510.15%
0.62
+135.57%
-1.76
-517.05%
0.42
Investing Cash Flow
-48.14
-193.36%
51.56
+2.20%
50.45
+155.67%
19.73
Cash Flow From Continuing Investing Activities
-48.14
-193.36%
51.56
+2.20%
50.45
+155.67%
19.73
Net Investment Purchase And Sale
-48.14
-193.36%
51.56
+2.20%
50.45
+155.67%
19.73
Purchase Of Investment
-83.83
-593.97%
-12.08
+86.65%
-90.46
-91.28%
-47.29
Sale Of Investment
35.69
-43.92%
63.64
-54.84%
140.92
+110.24%
67.03
Financing Cash Flow
93.56
+232034.78%
-0.04
+59.03%
-0.10
-100.22%
45.02
Cash Flow From Continuing Financing Activities
93.56
+232034.78%
-0.04
+59.03%
-0.10
-100.22%
45.02
Net Issuance Payments Of Debt
—
—
—
—
Repayment Of Debt
—
—
—
—
Long Term Debt Payments
—
—
—
—
Net Long Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
93.64
0.00
0.00
-100.00%
42.73
Proceeds From Stock Option Exercised
0.00
-100.00%
0.25
0.00
-100.00%
1.97
Net Other Financing Charges
-0.07
+74.56%
-0.29
-191.57%
-0.10
-130.42%
0.32
Changes In Cash
-0.36
-53.70%
-0.23
+82.02%
-1.30
+96.66%
-39.05
Beginning Cash Position
3.86
-5.73%
4.09
-24.17%
5.40
-87.86%
44.44
End Cash Position
3.50
-9.35%
3.86
-5.73%
4.09
-24.17%
5.40
Free Cash Flow
-45.79
+11.53%
-51.76
-0.19%
-51.66
+50.23%
-103.80
Interest Paid Supplemental Data
—
—
—
—
Common Stock Issuance
93.64
0.00
0.00
-100.00%
42.73
Issuance Of Capital Stock
93.64
0.00
0.00
-100.00%
42.73
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category